A prospective observational study of the efficacy and safety of CPT-11 based regimens for UGT1A1 genotype guided patients with metastatic colorectal cancer
Not Applicable
- Conditions
- Metastatic colorectal cancer (adenocarcinoma)
- Registration Number
- JPRN-jRCT1080220913
- Lead Sponsor
- DAIICHI SANKYO COMPANY, LIMITED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
1. Metastatic colorectal cancer (adenocarcinoma)
2. Patients to receiving FOLFIRI, CPT-11+S-1 and CPT-11 alone therapy (with or without molecular targeted agents)
Age requirement none
Exclusion Criteria
1. Contraindications of CPT-11
2. ECOG PS 3-4
3. Patients to receiving CPT-11 as adjuvant chemotherapy
4. History of a pelvic irradiation
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival<br>None
- Secondary Outcome Measures
Name Time Method Overall survival, Time to treatment failure, response rate, disease control rate and safety<br>None